Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 5;392(21):2174-2176.
doi: 10.1056/NEJMc2412487.

Bedaquiline Activity against Leprosy

Abdoulaye Fomba  1 , Fadima C Haidara  1 , Mamoudou Kodio  1 , Catherine Arama  1 , Emmanuelle Cambau  2 , Aurélie Chauffour  3 , Nicolas Veziris  3 , Bettina E Broeckling  4 , Alaine K Warren  4 , Bertrand Cauchoix  5 , Alexandre Alcaïs  6 , Laurent Marsollier  7 , Henri Assé  5 , Mary Jackson  4 , Samba Ousmane Sow  1 , Ousmane Faye  1 , Vincent Jarlier  3 , Stewart T Cole  8 , Charlotte Avanzi  4 , Alexandra Aubry  3 , Roch C Johnson  5
Affiliations

Bedaquiline Activity against Leprosy

Abdoulaye Fomba et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1:
Figure 1:. Biomarker responses to Bedaquiline treatment.
A. Bacteriological index of biopsies from the 17 patients who completed 2 months of bedaquiline treatment and the full course of multidrug therapy measured by microscopy at day 0, day 56 and at the end of multidrug therapy. B. Number of bacilli/mL calculated by RLEP qPCR in the same 17 patients from day 0, day 56 and end of multidrug therapy. C. Morphological index for the same 17 patients measured by microscopy at day 0, day 56 and end of multidrug therapy. D. Percentage decrease in the expression levels of esxA and hsp18 mRNA between day 0 and day 56 for patients (n=20) as measured by the molecular viability assay. Patient 20 was excluded due to no viability at day 0. Molecular viability was collected only for 21 patients at D0 and D56. E. Percentage of viable bacteria in mouse footpads measured by microscopy at day 0 and day 56 in 25 patients. The inset box highlights a zoomed-in view of the percentage of viable bacteria at D56. The viability threshold is noted as 0.04% (limit of detection of the method) and only one sample showed viability at D56. Descriptive statistic was calculated in GraphPad Prism v10.
See this image and copyright information in PMC

References

    1. WHO. Global leprosy update, 2017: reducing the disease burden due to leprosy. Weekly epidemiological record 2018;93:445–456.
    1. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307(5707):223–7. DOI: 10.1126/science.1106753. - DOI - PubMed
    1. Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med 2020;382(10):893–902. DOI: 10.1056/NEJMoa1901814. - DOI - PMC - PubMed
    1. Gelber R, Andries K, Paredes RM, Andaya CE, Burgos J. The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently. Antimicrob Agents Chemother 2009;53(9):3989–91. DOI: 10.1128/AAC.00722-09. - DOI - PMC - PubMed
    1. Davis GL, Ray NA, Lahiri R, et al. Molecular assays for determining Mycobacterium leprae viability in tissues of experimentally infected mice. PLoS Negl Trop Dis 2013;7(8):e2404. DOI: 10.1371/journal.pntd.0002404. - DOI - PMC - PubMed

LinkOut - more resources